Scientists at the University of Birmingham have developed a type of eye drop which could potentially revolutionise the treatment of one of the leading causes of blindness in the UK.
The results of the collaborative research, published today in Investigative Opthamology and Visual Science, could spell the end of painful injections directly into the eye to treat the increasingly common eye disorder known as age-related macular degeneration (AMD).
AMD affects more than 600,000 people in the UK and predictions suggest this figure could rise sharply in future because of an ageing population.
A painless condition which causes people to gradually lose their central vision, usually in both eyes, AMD is currently treated by repeated injections into the eye on a monthly basis over at least three years.
This is a problem because, apart from being an unpleasant procedure for patients to undergo, the injections can cause tearing and infections inside the eye and an increased risk of blindness.
Now scientists led by biochemist Dr Felicity de Cogan, from the University of Birmingham’s Institute of Inflammation and Ageing, have invented a method of delivering the injected drug as an eye drop instead, and their laboratory research has obtained the same outcomes as the injected drug.
The drop uses a cell-penetrating peptide (CPP) to deliver the drug to the relevant part of the eye within minutes.
Dr de Cogan said: “The CPP-drug has the potential to have a significant impact on the treatment of AMD by revolutionising drug-delivery options.
“Efficacious self-administered drug application by eye drop would lead to a significant reduction in adverse outcomes and health care costs compared with current treatments.
“The CPP-plus drug complex also has potential application to other chronic ocular diseases that require drug delivery to the posterior chamber of the eye.
“We believe this is going to be very important in terms of empowering of patients and reducing the cost of treatment to the NHS.”
The Latest on: Age-related macular degeneration
- LumiThera raises cash for medical device that uses light to fight vision losson August 16, 2019 at 6:02 am
LumiThera is developing a medical device for people with age-related macular degeneration. Above, a retina with patterns associated with the disease. (National Institute of Health Photo) Medical ...
- Clinical and genetic characteristics of pachydrusen in patients with exudative age-related macular degenerationon August 15, 2019 at 2:39 am
Drusen are accumulations of extracellular material between the retinal pigment epithelium (RPE) and Bruch’s membrane. They have been considered to result from the normal aging process and may ...
- Kodiak Sciences Announces Second Quarter 2019 Financial Results and Recent Business Highlightson August 14, 2019 at 2:30 am
age-related macular degeneration (AMD), diabetic macular edema (DME), and macular edema due to retinal vein occlusion (RVO) were presented at the American Society of Retina Specialists (ASRS ...
- Outlook Therapeutics Provides Business Update and Reports Financial Results for Third Quarter of Fiscal 2019on August 14, 2019 at 2:15 am
the second of the two ongoing adequate and well controlled Phase 3 clinical trials evaluating ONS-5010 against ranibizumab (Lucentis®) for wet age related macular degeneration (wet AMD). The trial is ...
- Novartis teams with interior designer to help wet AMD patientson August 13, 2019 at 10:07 pm
Novartis is teaming up with celebrity interior designer Nate Berkus to launch My Home in Sight, a program that aims to raise awareness of the daily impact of wet age-related macular degeneration (wet ...
via Google News and Bing News